IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by First Manhattan CO. LLC.

First Manhattan CO. LLC. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 205,551 shares of the medical research company's stock after buying an additional 15,115 shares during the quarter. First Manhattan CO. LLC. owned approximately 0.11% of IQVIA worth $40,393,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Synergy Asset Management LLC acquired a new position in IQVIA in the 4th quarter valued at about $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA in the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. acquired a new position in IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. raised its stake in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA in the 4th quarter valued at about $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Down 2.9%

Shares of IQV traded down $4.39 during trading on Friday, reaching $148.90. The company's stock had a trading volume of 1,677,229 shares, compared to its average volume of 1,469,448. The company has a fifty day moving average of $163.91 and a two-hundred day moving average of $188.09. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a market cap of $25.76 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period in the prior year, the company posted $2.54 EPS. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on IQV. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Mizuho lowered their price target on IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Barclays lowered their price target on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a report on Wednesday. Finally, Truist Financial decreased their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a report on Thursday, April 10th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $231.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.